NASDAQ : EPRX
Eupraxia Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 6.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 449.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 442.44M |
| Enterprise Value | 336.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 65.91M |
| Shares Outstanding | 65.91M |
| Shares Change (YoY) | +47.80% |
| Shares Change (QoQ) | +16.77% |
| Owned by Insiders (%) | 15.53% |
| Owned by Institutions (%) | 43.70% |
| Float | 55.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.47 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.00 |
| Quick Ratio | 15.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -66.70% |
| Return on Assets (ROA) | -43.66% |
| Return on Invested Capital (ROIC) | -46.80% |
| Return on Capital Employed (ROCE) | -43.47% |
| Weighted Average Cost of Capital (WACC) | 10.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 55,002 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +20.58% |
| 50-Day Moving Average | 7.59 |
| 200-Day Moving Average | 7.30 |
| Relative Strength Index (RSI) | 41.51 |
| Average Volume (20 Days) | 678,507 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.54M |
| Short Previous Month | 6.80M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 11.75% |
| Short Ratio (days to cover) | 7.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.11M |
| Pretax Income | -50.18M |
| Net Income | -52.68M |
| EBITDA | -56.87M |
| EBIT | -57.11M |
| Earnings Per Share (EPS) | -$1.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 133.66M |
| Total Debt | 1.84M |
| Net Cash | 131.82M |
| Net Cash Per Share | $2.00 |
| Equity (Book Value) | 129.67M |
| Book Value Per Share | 1.55 |
| Working Capital | 128.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -37.47M |
| Capital Expenditures | -753,723 |
| Depreciation & Amortization | 239,363 |
| Net Borrowing | n/a |
| Free Cash Flow | -38.23M |
| FCF Per Share | -$0.58 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.80% |
| Shareholder Yield | -47.80% |
| Earnings Yield | -15.08% |
| FCF Yield | -8.50% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $16.61 |
| Price Target Difference | 147.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |